Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under review

Biocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company is in advanced talks with minority investors for a share swap, considering various value creation options including an IPO or merger. This move aims to address acquisition-related debt and unlock shareholder value.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rdbjDKk
via IFTTT